Novo Nordisk has expanded its partnership with Valo Health to advance new therapies for type 2 diabetes, obesity and cardiometabolic diseases, leveraging AI and extensive human datasets.

Novo Nordisk has almost doubled the scale of an R&D alliance with Valo Health – a specialist in applying artificial intelligence to drug discovery – adding up to nine programmes to the ...

Jan 8 (Reuters) - Danish drugmaker Novo Nordisk (NOVOb.CO), opens new tab and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to develop new treatments for ...

Under the expanded partnership, Novo Nordisk has agreed to pay Valo $190 million upfront, up-to-$4.6 billion in milestones, plus R&D funding and potential royalty payments. “This level of ...

Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the final quarter of ...

Novo Nordisk reported Q4 sales of $11.96 billion, beating estimates. The company plans a new phase 3 trial for CagriSema in ...

Novo Nordisk's U.S.-listed shares are rising 4% in premarket trading after the Ozempic and Wegovy maker's better-than-estimated quarterly results offset slower 2025 sales growth projections amid ...

Novo Nordisk stock gained, lifted by strong sales growth and guidance from the maker of Wegovy and Ozempic. Shares in Novo, one of Europe's largest listed companies, advanced nearly 3% in Denmark. Dig ...

Novo Nordisk (NVO) stock and Eli Lilly (LLY) stock higher as Novo (NVO) reports strong Q4 2024 earnings, driven by sales ...